FDA Grants Fast Track Designation to 225Ac-FL-020 for Metastatic Castration-Resistant Prostate Cancer
核心洞察
The FDA has awarded Fast Track Designation to 225Ac-FL-020, Full-Life Technologies (搜索)' investigational PSMA (搜索)-targeting radiopharmaceutical for treating metastatic castration-resistant prostate cancer (搜索).
The designation enables more frequent FDA engagement, eligibility for accelerated approval, and priority review to potentially accelerate patient access to this novel therapy.
Preclinical data demonstrated superior anti-tumor activity compared to 225Ac-PSMA-617 in xenograft models, with favorable safety profiles warranting clinical development.
Full-Life Technologies (搜索) announced that the US FDA has granted Fast Track Designation for 225Ac-FL-020, the company's lead radiopharmaceutical targeting prostate-specific membrane antigen (搜索) (PSMA (搜索)) for the treatment of metastatic castration-resistant prostate cancer (搜索) (mCRPC (搜索)). This regulatory milestone highlights the potential of the investigational therapy to address a critical unmet medical need in advanced prostate cancer (搜索) treatment.
Regulatory Benefits and Development Acceleration
The Fast Track program is designed to facilitate the development and regulatory review of novel potential therapies intended to treat serious conditions and fill an unmet need. With this designation, 225Ac-FL-020 can benefit from more frequent engagement with the FDA, eligibility for accelerated approval, and priority review.
"The FDA Fast Track Designation for 225Ac-FL-020 underscores the critical need for innovative and effective treatments for mCRPC (搜索)," said Steffen Heeger, MD, MSc, Chief Medical Officer of Full-Life Technologies (搜索). "This designation will enable us to collaborate more closely with the FDA throughout the development process, potentially accelerating the availability of 225Ac-FL-020 to patients."
Clinical Development Progress
In May 2024, the FDA cleared an investigational new drug application for 225Ac-FL-020 to initiate clinical trials in the US and globally in patients with prostate cancer (搜索). The phase 1 clinical trial, set to launch this year, will assess the safety, tolerability, and preliminary anti-tumor activity of 225Ac-FL-020 in patients with mCRPC (搜索).
Mechanism and Preclinical Efficacy
225Ac-FL-020 is an actinium-225 (搜索) (225Ac)-based PSMA (搜索) radioligand therapy designed to selectively attack cancer cells. Preclinical data presented at the 2024 Annual Meeting of the American Association for Cancer Research demonstrated the therapy's promising characteristics.
The preclinical study assessed the binding affinity of the non-labeled vector FL-020 against PSMA (搜索) in vitro, showing that FL-020 bound to LNCaP cells with an IC50 value of 51.55 nM. The research also demonstrated high and sustained tumor uptake and fast systemic clearance with Indium-111 (搜索) (111In)-FL-020 in PSMA high LNCaP tumor-bearing nude mice.
Superior Performance and Safety Profile
The study indicated high selectivity of FL-020, with off-target screening showing that less than 50% of inhibition of binding or activity was observed by FL-020 at 10 μM against 85 targets, including receptors, ions, channels, enzymes, and transporters.
Investigators compared the anti-tumor activity of 225Ac-FL-020 in LNCaP xenograft models to that of 225Ac-PSMA-617. Findings showed that 225Ac-FL-020 demonstrated superior anti-tumor activity to 225Ac-PSMA-617 at the dose level of 10 KBq/mouse in the LNCaP xenograft model. Additionally, the therapy had a favorable safety profile as indicated by body weight and hematological parameters.
Based on these data, the authors concluded, "Taken together, these results collectively demonstrate that 225Ac-FL-020 is a potent and selective PSMA (搜索)-targeting radioligand therapy candidate with superior anti-tumor activity and a favorable safety profile warranting further clinical development."